Oncotelic Therapeutics, Inc. (OTLC)
OTCMKTS · Delayed Price · Currency is USD
0.0134
+0.0002 (1.52%)
At close: Nov 16, 2026
Oncotelic Therapeutics Revenue
Oncotelic Therapeutics had revenue of $250.00K in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $250.00K. That makes Oncotelic Therapeutics the 45,305th largest company in the world by revenue and 6,568th in the United States.
Revenue (ttm)
250.00K
Revenue Growth
n/a
P/S Ratio
24.52
Revenue / Employee
6.10K
Employees
43
Market Cap
6.13M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 70.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zeo ScientifiX | 8.80M |
| Adaptimmune Therapeutics | 5.92M |
| OSR Health | 1.71M |
| Orgenesis | 1.04M |
| TRON Group | 1.01M |
| America Great Health | 363.33K |
| Eastgate Biotech | 137.64K |
Oncotelic Therapeutics News
- 14 days ago - 3 Hot Stocks with Recent Insider Buying - TipRanks
- 21 days ago - Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature - GlobeNewsWire
- 27 days ago - Oncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled Discovery - GlobeNewsWire
- 6 weeks ago - PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026 - GlobeNewsWire
- 3 months ago - Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th - GlobeNewsWire
- 3 months ago - Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus) - GlobeNewsWire
- 4 months ago - Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway - GlobeNewsWire
- 4 months ago - Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003 - GlobeNewsWire